|
LM_ID
|
Common Name
|
Systematic Name
|
Main class
|
Sub class
|
Mass
|
Formula
|
|
LMFA04000068
|
4S-hydroperoxy-17S-HDHA
|
4S-hydroperoxy-17S-hydroxy-5E,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid
|
Docosanoids [FA04]
|
Other Docosanoids [FA0400]
|
376.22
|
C22H32O5
|
|
LMFA04010177
|
10,13-diepi-10-D4c-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1S,2S,5S)-5-hydroxy-3-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010176
|
10,13-diepi-10-D4t-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1R,2R,5S)-5-hydroxy-3-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010305
|
10,13-diepi-10-E4c-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1S,2S,3R)-3-hydroxy-5-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010304
|
10,13-diepi-10-E4t-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1R,2R,3R)-3-hydroxy-5-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010245
|
10,17-diepi-17-D4c-NeuroP
|
(4Z,7Z)-9-((1S,2S,5S)-5-hydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-3-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010244
|
10,17-diepi-17-D4t-NeuroP
|
(4Z,7Z)-9-((1R,2R,5S)-5-hydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-3-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010373
|
10,17-diepi-17-E4c-NeuroP
|
(4Z,7Z)-9-((1S,2S,3R)-3-hydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010372
|
10,17-diepi-17-E4t-NeuroP
|
(4Z,7Z)-9-((1R,2R,3R)-3-hydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010183
|
10-D4c-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1R,2S,5S)-5-hydroxy-3-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010186
|
10-D4t-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1S,2R,5S)-5-hydroxy-3-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010311
|
10-E4c-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1R,2S,3R)-3-hydroxy-5-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010314
|
10-E4t-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1S,2R,3R)-3-hydroxy-5-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010175
|
10-epi-10-D4c-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1R,2S,5S)-5-hydroxy-3-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010178
|
10-epi-10-D4t-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1S,2R,5S)-5-hydroxy-3-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010303
|
10-epi-10-E4c-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1R,2S,3R)-3-hydroxy-5-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010306
|
10-epi-10-E4t-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1S,2R,3R)-3-hydroxy-5-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010249
|
10-epi-17-D4c-NeuroP
|
(4Z,7Z)-9-((1S,2S,5S)-5-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-3-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010248
|
10-epi-17-D4t-NeuroP
|
(4Z,7Z)-9-((1R,2R,5S)-5-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-3-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010377
|
10-epi-17-E4c-NeuroP
|
(4Z,7Z)-9-((1S,2S,3R)-3-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010376
|
10-epi-17-E4t-NeuroP
|
(4Z,7Z)-9-((1R,2R,3R)-3-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010169
|
10-epi-7-D4c-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1S,2S,5S)-5-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-3-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010168
|
10-epi-7-D4t-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1R,2R,5S)-5-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-3-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010297
|
10-epi-7-E4c-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1S,2S,3R)-3-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010296
|
10-epi-7-E4t-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1R,2R,3R)-3-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010199
|
11-D4c-NeuroP
|
3-((1R,2S,5S)-5-hydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-3-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010202
|
11-D4t-NeuroP
|
3-((1S,2R,5S)-5-hydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-3-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010327
|
11-E4c-NeuroP
|
3-((1R,2S,3R)-3-hydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010330
|
11-E4t-NeuroP
|
3-((1S,2R,3R)-3-hydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010191
|
11-epi-11-D4c-NeuroP
|
3-((1R,2S,5R)-5-hydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-3-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010194
|
11-epi-11-D4t-NeuroP
|
3-((1S,2R,5R)-5-hydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-3-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010319
|
11-epi-11-E4c-NeuroP
|
3-((1R,2S,3S)-3-hydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010322
|
11-epi-11-E4t-NeuroP
|
3-((1S,2R,3S)-3-hydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010209
|
13,16-diepi-13-D4c-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1S,2S,5S)-2-ethyl-5-hydroxy-3-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010208
|
13,16-diepi-13-D4t-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1R,2R,5S)-2-ethyl-5-hydroxy-3-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010337
|
13,16-diepi-13-E4c-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1S,2S,3R)-2-ethyl-3-hydroxy-5-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010336
|
13,16-diepi-13-E4t-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1R,2R,3R)-2-ethyl-3-hydroxy-5-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010261
|
13,20-diepi-20-D4c-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2S,5S)-5-hydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)-3-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010260
|
13,20-diepi-20-D4t-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2R,5S)-5-hydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)-3-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010389
|
13,20-diepi-20-E4c-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2S,3R)-3-hydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010388
|
13,20-diepi-20-E4t-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2R,3R)-3-hydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010215
|
13-D4c-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1R,2S,5S)-2-ethyl-5-hydroxy-3-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010218
|
13-D4t-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1S,2R,5S)-2-ethyl-5-hydroxy-3-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010343
|
13-E4c-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1R,2S,3R)-2-ethyl-3-hydroxy-5-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010346
|
13-E4t-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1S,2R,3R)-2-ethyl-3-hydroxy-5-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010185
|
13-epi-10-D4c-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1S,2S,5S)-5-hydroxy-3-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010184
|
13-epi-10-D4t-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1R,2R,5S)-5-hydroxy-3-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010313
|
13-epi-10-E4c-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1S,2S,3R)-3-hydroxy-5-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010312
|
13-epi-10-E4t-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1R,2R,3R)-3-hydroxy-5-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010207
|
13-epi-13-D4c-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1R,2S,5S)-2-ethyl-5-hydroxy-3-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|